Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now!

Mar 18, 2015

assdd

Launch of DelveInsight’s Antibody-Drug Conjugate Report

DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.

Downloads

Article in PDF

Recent Articles

Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the ...

DelveInsight’s Infectious disorders based Gene Therapy Reports

DelveInsight’s Otolaryngology based Gene Therapy Reports

DelveInsight’s Cardiovascular disorders based Gene Therapy Reports

DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports

Around 253 ADCs in Oncology

Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women’s health, gastrointestinal and ophthalmology.

Four Potential ADCs in Phase III Pipeline

Companies are trying its already marketed ADC for different combinations and for different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca’s Moxetumomab Pasudotox and Pfizer’s Inotuzumab Ozogamicin for Relapsed/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.

Report Pricing

Single User License: 3500 USD

Site License: 7000 USD

Global License: 10500 USD

For more information email us at info@delveinsight.com or visit us at www.delveinsight.com

Ask for Sample Pages now!

[contact-form][contact-field label=’Name’ type=’name’ required=’1’/][contact-field label=’Email’ type=’email’ required=’1’/][contact-field label=’Website’ type=’url’/][contact-field label=’Comment’ type=’textarea’ required=’1’/][/contact-form]